Clinical trial registry record

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 3, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04964089
Last registry update
July 3, 2024
Status
Completed
Phase
Phase 3
Sponsor
Kodiak Sciences Inc
Enrollment
557
Countries
United States, Puerto Rico
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
557
Population
ALL · 50 Years
Duration
2021-06-23 to 2023-04-06
Intervention
KSI-301; Aflibercept; Sham Procedure
Comparator
Aflibercept (Treatment Group B)
Outcomes measured
Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44…; Mean Change in Best Corrected Visual Acuity (BCVA) by Visit Over Time — Day 1 to Week 48; Proportion of Patients Who Gain ≥ 5, ≥10 and ≥15 Letters From Baseline Over Time — Day 1 to Week 48; Proportion of Patients Who Lost ≥ 5, ≥10 and ≥15 Letters From Baseline Over Time — Day 1 to Week 48; Proportion of Participants With BCVA Snellen Equivalent of 20/40 or Better Over Time (≥69 ETDRS Letters) — Day 1 to Wee…; Proportion of Participants With BCVA Snellen Equivalent of 20/200 or Worse Over Time (≤38 ETDRS Letters) — Day 1 to Wee…; Mean Change in OCT Central Subfield Retinal Thickness (CST) From Baseline to the Average of Weeks 40, 44 and 48 and Ove…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON